SCHEMBL5763676

SCHEMBL5763676

CCC[C@@H](N)C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.40
NOS3 P29474 1/20 0.40
NOS2 P35228 1/20 0.40
LTA4H P09960 1/20 0.39
SLC1A2 P43004 3/20 0.38
SLC1A1 P43005 3/20 0.38
GRIK1 P39086 3/20 0.38
GRIK2 Q13002 3/20 0.38
SLC1A3 P43003 2/20 0.38
CTSK P43235 5/20 0.37
CTSS P25774 2/20 0.37
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
LMNA P02545 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67350 1.00 NOS1 (0.40) NOS1NOS3NOS2LTA4HSLC1A2
SCHEMBL17449764 1.00 NOS1 (0.40) NOS1NOS3NOS2LTA4HSLC1A2
SCHEMBL67349 1.00 NOS1 (0.40) NOS1NOS3NOS2LTA4HSLC1A2
Hydrochloric Acid SCHEMBL311215 0.98 NOS1 (0.39) NOS1NOS3NOS2LTA4HSLC1A2
Bromide SCHEMBL8760868 0.98 NOS1 (0.39) NOS1NOS3NOS2LTA4HSLC1A2
Hydrochloric Acid SCHEMBL952472 0.98 NOS1 (0.39) NOS1NOS3NOS2LTA4HSLC1A2
SCHEMBL3294154 0.89 NOS1 (0.42) NOS1NOS3NOS2LTA4HSLC1A2
SCHEMBL5967210 0.88 SLC1A2 (0.46) NOS1NOS3NOS2SLC1A2SLC1A1
SCHEMBL7266730 0.88 SLC1A2 (0.46) NOS1NOS3NOS2SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL5967206 0.86 SLC1A2 (0.44) NOS1LTA4HSLC1A2SLC1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192133-B1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2006-11-02 EP disclosed
US-6593346-B2 Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. MERCK & CO. INC. 2003-07-15 US disclosed
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-08-29 US disclosed
EP-1192133-A1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2002-04-03 EP disclosed
US-6358979-B1 FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS MERCK & CO., INC. 2002-03-19 US disclosed
WO-2000076972-A1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity CCR1, CCR3, CCR5 NOS1 1458/4885NOS3 928/4885NOS2 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.